%0 Journal Article
%T The challenge of relapsed/refractory myeloma: An emerging role of bortezomib
%A Bhargav Vyasa
%A Arun Maseeh
%J Clinical Cancer Investigation Journal
%@ 2278-0513
%D 2012
%V 1
%N 4
%R 10.4103/2278-0513.106247
%P 190-195
%X The treatment of multiple myeloma (MM) has undergone significant developments in recent years. The availability of the novel agents includes thalidomide and its analogs, proteasome inhibitors, arsenic trioxide, farnesyltransferase inhibitors 2-methoxyestradiol and lenalidomide has extended treatment options and has improved the outcome and quality of life of patients with MM. This review presents the totality of evidence through a systematic review that assessed the efficacy, safety or toxicity of bortezomib in patients with relapsed/refractory myeloma with or without concomitant complications. This review has precisely covered the role of bortezomib in patients with relapsed/refractory myeloma and not the newly detected populace.
%U https://ccij-online.org/article/the-challenge-of-relapsed-refractory-myeloma:-an-emerging-role-of-bortezomib-51